|
1
|
Sheng W, Ogunwobi OO, Chen T, Zhang J,
George TJ, Liu C and Fan ZH: Capture, release and culture of
circulating tumor cells from pancreatic cancer patients using an
enhanced mixing chip. Lab Chip. 14:89–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Babayan A, Hannemann J, Spötter J, Müller
V, Pantel K and Joosse SA: Heterogeneity of estrogen receptor
expression in circulating tumor cells from metastatic breast cancer
patients. PLoS One. 8:e750382013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu
H, Li S, Hu Z, Wu S, Liu B, et al: Circulating tumor cells in
HER2-positive metastatic breast cancer patients: A valuable
prognostic and predictive biomarker. BMC Cancer. 13:2022013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Onstenk W, Gratama JW, Foekens JA and
Sleijfer S: Towards a personalized breast cancer treatment approach
guided by circulating tumor cell (CTC) characteristics. Cancer
Treat Rev. 39:691–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torino F, Bonmassar E, Bonmassar L, De
Vecchis L, Barnabei A, Zuppi C, Capoluongo E and Aquino A:
Circulating tumor cells in colorectal cancer patients. Cancer Treat
Rev. 39:759–772. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yokobori T, Iinuma H, Shimamura T, Imoto
S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, et
al: Plastin3 is a novel marker for circulating tumor cells
undergoing the epithelial-mesenchymal transition and is associated
with colorectal cancer prognosis. Cancer Res. 73:2059–2069. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Franken B, de Groot MR, Mastboom WJB,
Vermes I, van der Palen J, Tibbe AGJ and Terstappen LWMM:
Circulating tumor cells, disease recurrence and survival in newly
diagnosed breast cancer. Breast Cancer Res. 14:R1332012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hou JM, Krebs MG, Lancashire L, Sloane R,
Backen A, Swain RK, Priest LJC, Greystoke A, Zhou C, Morris K, et
al: Clinical significance and molecular characteristics of
circulating tumor cells and circulating tumor microemboli in
patients with small-cell lung cancer. J Clin Oncol. 30:525–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsusaka S, Suenaga M, Mishima Y,
Kuniyoshi R, Takagi K, Terui Y, Mizunuma N and Hatake K:
Circulating tumor cells as a surrogate marker for determining
response to chemotherapy in Japanese patients with metastatic
colorectal cancer. Cancer Sci. 102:1188–1192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park Y, Kitahara T, Urita T, Yoshida Y and
Kato R: Expected clinical applications of circulating tumor cells
in breast cancer. World J Clin Oncol. 2:303–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stott SL, Lee RJ, Nagrath S, Yu M,
Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z,
et al: Isolation and characterization of circulating tumor cells
from patients with localized and metastatic prostate cancer. Sci
Transl Med. 2:25ra232010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okegawa T, Nutahara K and Higashihara E:
Association of circulating tumor cells with tumor-related
methylated DNA in patients with hormone-refractory prostate cancer.
Int J Urol. 17:466–475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okegawa T, Nutahara K and Higashihara E:
Prognostic significance of circulating tumor cells in patients with
hormone refractory prostate cancer. J Urol. 181:1091–1097. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wülfing P, Borchard J, Buerger H, Heidl S,
Zänker KS, Kiesel L and Brandt B: HER2-positive circulating tumor
cells indicate poor clinical outcome in stage I to III breast
cancer patients. Clin Cancer Res. 12:1715–1720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohnaga T, Shimada Y, Moriyama M, Kishi H,
Obata T, Takata K, Okumura T, Nagata T, Muraguchi A and Tsukada K:
Polymeric microfluidic devices exhibiting sufficient capture of
cancer cell line for isolation of circulating tumor cells. Biomed
Microdevices. 15:611–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dickson Nora M, Tsinberg P, Tang Z,
Bischoff FZ, Wilson T and Leonard EF: Efficient capture of
circulating tumor cells with a novel immunocytochemical
microfluidic device. Biomicrofluidics. 5:34119–3411915. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stott SL, Hsu CH, Tsukrov DI, Yu M,
Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK,
et al: Isolation of circulating tumor cells using a
microvortex-generating herringbone-chip. Proc Natl Acad Sci USA.
107:18392–18397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gleghorn JP, Pratt ED, Denning D, Liu H,
Bander NH, Tagawa ST, Nanus DM, Giannakakou PA and Kirby BJ:
Capture of circulating tumor cells from whole blood of prostate
cancer patients using geometrically enhanced differential
immunocapture (GEDI) and a prostate-specific antibody. Lab Chip.
10:27–29. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Punnoose EA, Atwal SK, Spoerke JM, Savage
H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, et
al: Molecular biomarker analyses using circulating tumor cells.
PLoS One. 5:e125172010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martowicz A, Spizzo G, Gastl G and
Untergasser G: Phenotype-dependent effects of EpCAM expression on
growth and invasion of human breast cancer cell lines. BMC Cancer.
12:5012012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pecot CV, Bischoff FZ, Mayer JA, Wong KL,
Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW,
et al: A novel platform for detection of CK+ and CK- CTCs. Cancer
Discov. 1:580–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sieuwerts AM, Kraan J, Bolt J, van der
Spoel P, Elstrodt F, Schutte M, Martens JWM, Gratama JW, Sleijfer S
and Foekens JA: Anti-epithelial cell adhesion molecule antibodies
and the detection of circulating normal-like breast tumor cells. J
Natl Cancer Inst. 101:61–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prang N, Preithner S, Brischwein K, Göster
P, Wöppel A, Müller J, Steiger C, Peters M, Baeuerle PA and da
Silva AJ: Cellular and complement-dependent cytotoxicity of
Ep-CAM-specific monoclonal antibody MT201 against breast cancer
cell lines. Br J Cancer. 92:342–349. 2005.PubMed/NCBI
|
|
26
|
Galletti G, Sung MS, Vahdat LT, Shah MA,
Santana SM, Altavilla G, Kirby BJ and Giannakakou P: Isolation of
breast cancer and gastric cancer circulating tumor cells by use of
an anti HER2-based microfluidic device. Lab Chip. 14:147–156. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kirby BJ, Jodari M, Loftus MS, Gakhar G,
Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP,
et al: Functional characterization of circulating tumor cells with
a prostate-cancer-specific microfluidic device. PLoS One.
7:e359762012. View Article : Google Scholar : PubMed/NCBI
|
